Cervical cancer trials in South Korea

In South Korea 22 Also abroad 532

22 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Where
Daegu, Goyang-si, Gyeonggi-do, Seoul
Age
15 years and over
People
800 worldwide
Run by
AstraZeneca
See details and how to joinNCT06079671 · EU 2023-504374-38-00
Phase 3Taking people
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Where
Goyang-si, Jongno-gu, Seodaemun-Gu, Seoul
Age
18 years and over
People
1,023 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07216703 · EU 2025-521514-26-00
Phase 1/2Taking people
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Where
Seoul
Age
18 years and over
People
952 worldwide
Run by
Genmab
See details and how to joinNCT05579366
Phase 1Taking people
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Where
Goyang-si Gyeonggi-do
Age
18 years and over
People
575 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00
Phase 1Taking people
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Where
Seoul
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00
Phase 2Taking people
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Jongno -Gu, Seoul
Age
18 years and over
People
111 worldwide
Run by
Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Daegu, Gyeonggi-do, Seongnam, Seoul
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1/2Taking people
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Where
Daejeon, Seoul, Suwon
Age
18 years and over
People
317 worldwide
Run by
GI Innovation, Inc.
See details and how to joinNCT04977453
No phaseTaking people
Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer
Where
Seoul
Age
19 years and over
People
1,000
Run by
Seoul National University Hospital
See details and how to joinNCT06977594
Phase 2Taking people
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
Where
Incheon, Namdong-gu, Seoul
Age
18 years to 64 years
People
257 worldwide
Run by
AstraZeneca
See details and how to joinNCT06535607 · EU 2025-523947-36-00
No phaseTaking people
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
Where
Seongnam-si, Seoul
Age
18 years and over
People
840 worldwide
Run by
GOG Foundation
See details and how to joinNCT04831580
Phase 1Taking people
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Where
Cheongju-si, Goyang-si, Seoul
Age
18 years and over
People
1,006 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT04389632 · EU 2023-508469-34-00
Phase 1/2Taking people
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
Where
Seoul
Age
18 years and over
People
80
Run by
Yuhan Corporation
See details and how to joinNCT06975410
Phase 2Taking people
Intra-lesional Tumor Boost for Bulky Cervical Cancer
Where
Seongnam-si
Age
19 years to 80 years
People
17
Run by
Seoul National University Bundang Hospital
See details and how to joinNCT07435376
Phase 2Taking people
Definitive Hypofractionated Intensity-modulated Radiation Theraphy With Concurrent Chemotherapy in Cervical Cancer
Where
Seoul
Age
20 years and over
People
34
Run by
Samsung Medical Center
See details and how to joinNCT07439497
No phaseNot yet taking people in South Korea
Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cervical Cancer
Where
Seoul
People
600
Run by
Asan Medical Center
See details and how to joinNCT07382505
No phaseNot yet taking people in South Korea
Minimally Invasive Radical Hysterectomy Using Endoscopic Stapler in Stage IB2 or IIA1 Cervical Cancer
Where
Seoul
Age
20 years and over
People
494
Run by
Seoul National University Hospital
See details and how to joinNCT07256977
No phaseTaking people
Therapeutic Effect of Surgical Debulking of Metastatic Lymph Nodes in Cervical Cancer Stage IIICr
Where
Ansan-si, Busan, Changwon, Cheonan, Daegu, Goyang-si, Hwasun, Incheon, Seongnam-si, Seoul, Yangsan
Age
20 years to 70 years
People
240 worldwide
Run by
CHA University
See details and how to joinNCT05421650
Phase 3Taking people
Comparison of Conventional and Hypofractionated IMRT in High-Risk Cervical Cancer Post-Radical Hysterectomy
Where
Seoul
Age
20 years to 75 years
People
248
Run by
Samsung Medical Center
See details and how to joinNCT06509724
Phase 1/2Taking people
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
Where
Goyang-si, Seoul
Age
18 years and over
People
125
Run by
GeneMedicine Co., Ltd.
See details and how to joinNCT06265025
No phaseTaking people
Safety of Minimally Invasive Surgery Using Endoscopic Stapler in Early Stage Cervical Cancer Patients (SOLUTION)
Where
Seoul, Suwon
Age
20 years and over
People
124
Run by
Seoul National University Hospital
See details and how to joinNCT04370496
No phaseTaking people
Development and Management of Registry in Patients With Gynecologic Cancer in Korea
Where
Seoul
Age
18 years and over
People
13,500
Run by
Asan Medical Center
See details and how to joinNCT05912972